NASDAQ:CDAK Codiak BioSciences (CDAK) Stock Price, News & Analysis → Millionaire-Making “Wealth Pattern” Just Repeated on April 22 (From Paradigm Press) (Ad) Free CDAK Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.0016▼$0.001650-Day Range N/A52-Week Range$0.05▼$6.98VolumeN/AAverage Volume1.37 million shsMarket Capitalization$58,928.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Codiak BioSciences alerts: Email Address Ad Porter & CompanyThe new masters of energyAccording to one source, this new grid could soon provide energy to “one billion people in the world who don’t have access to electricity right now.” And early investors could make a fortune.Click here to get all the details. About Codiak BioSciences Stock (NASDAQ:CDAK)Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More Ad Porter & CompanyThe new masters of energyAccording to one source, this new grid could soon provide energy to “one billion people in the world who don’t have access to electricity right now.” And early investors could make a fortune.Click here to get all the details. CDAK Stock News HeadlinesJanuary 13, 2024 | morningstar.comMarvel Biosciences Corp MRVLMay 19, 2023 | finance.yahoo.comMariana Oncology Expands Management Team, Appoints Linda Bain Chief Operating Officer and Chief Financial OfficerApril 15, 2023 | reuters.comCDAK.OApril 2, 2023 | benzinga.comHow Does Codiak BioSciences Inc (CDAK) Stock Rank on Wall Street Friday?March 27, 2023 | finance.yahoo.comCodiak BioSciences Files For Chapter 11 BankruptcyMarch 27, 2023 | marketwatch.comCodiak BioSciences Shares Hit 52-Week Low After Bankruptcy FilingMarch 27, 2023 | bizjournals.comStruggling MD Anderson spinout files for bankruptcy protectionMarch 27, 2023 | benzinga.comCodiak BioSciences shares are trading lower after the company voluntarily filed for protection under Chapter 11 bankruptcy.March 27, 2023 | finanznachrichten.deCodiak BioSciences, Inc.: Codiak BioSciences to Pursue Asset Sale through Voluntary Chapter 11 ProcessMarch 27, 2023 | reuters.comCOVID vaccine developer Codiak files for US bankruptcy protectionMarch 27, 2023 | msn.comCodiak Bio Tumbles on Bankruptcy FilingMarch 27, 2023 | markets.businessinsider.comCodiak BioSciences Voluntarily Files For Bankruptcy ProtectionMarch 27, 2023 | finance.yahoo.comCodiak BioSciences to Pursue Asset Sale through Voluntary Chapter 11 ProcessMarch 22, 2023 | seekingalpha.comCDAK Codiak BioSciences, Inc.March 3, 2023 | msn.comLaurion Capital Management Now Owns 9.60% of Codiak BioSciences (CDAK)February 21, 2023 | bizjournals.comBlood disorder startup Hemab Therapeutics raises $135MNovember 28, 2022 | finance.yahoo.comCodiak BioSciences to Participate 5th Annual Evercore ISI HealthCONx ConferenceNovember 10, 2022 | finance.yahoo.comCodiak Presents Preclinical Data on exoASO™-STAT6 and exoASO™-C/EBPβ Programs at the Society for Immunotherapy of Cancer (SITC) 2022 Annual MeetingNovember 9, 2022 | finance.yahoo.comCodiak BioSciences Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagNovember 4, 2022 | finance.yahoo.comCodiak BioSciences, Inc. (CDAK) Reports Q3 Loss, Lags Revenue EstimatesNovember 3, 2022 | technews.tmcnet.comCodiak BioSciences Reports Third Quarter 2022 Financial Results and Operational ProgressNovember 3, 2022 | finance.yahoo.comCodiak BioSciences Reports Third Quarter 2022 Financial Results and Operational ProgressOctober 19, 2022 | finance.yahoo.comAll You Need to Know About Codiak BioSciences, Inc. (CDAK) Rating Upgrade to Strong BuyOctober 12, 2022 | finance.yahoo.comCodiak Presents Preclinical Data Demonstrating its Pan Beta-Coronavirus Vaccine Elicits Broad Protective Immunity Against Known Variants of SARS-CoV-2 and Related SarbecovirusesOctober 6, 2022 | finance.yahoo.comBiohaven (BHVN) Stock Up on Spin-Off Transaction FinalizationSee More Headlines Receive CDAK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Codiak BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today6/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CDAK CUSIPN/A CIK1659352 Webwww.codiakbio.com Phone617-949-4100FaxN/AEmployees102Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,160,000.00 Net Margins-51.13% Pretax Margin-51.13% Return on Equity-109.51% Return on Assets-34.44% Debt Debt-to-Equity Ratio0.66 Current Ratio4.24 Quick Ratio4.24 Sales & Book Value Annual Sales$33.57 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$2.39 per share Price / Book0.00Miscellaneous Outstanding Shares36,830,000Free Float33,810,000Market Cap$58,928.00 OptionableNot Optionable Beta3.71 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Douglas Edward Williams Ph.D. (Age 64)Pres, CEO & Director Comp: $970.77kMs. Linda Cathavina Bain CPA (Age 52)CFO & Treasurer Comp: $602.54kDr. Sriram Sathyanarayanan Ph.D. (Age 50)Chief Scientific Officer Comp: $502.17kDr. Konstantin Konstantinov Ph.D. (Age 64)Chief Technology Officer Mr. Christopher J. M. TaylorVP of Investor Relations & Corp. CommunicationsMs. Yalonda Howze (Age 50)Exec. VP, Chief Legal Officer, Chief Compliance Officer & Corp. Sec. Ms. Nicole Barna (Age 48)Sr. VP of HR Dr. David J. Mauro M.D. (Age 57)Ph.D., Chief Medical Officer Dr. Benny Sorensen M.D. (Age 48)Ph.D., Member of Scientific Advisory Board & Consultant More ExecutivesKey CompetitorsPeak BioNASDAQ:PKBOIgnyte AcquisitionNASDAQ:IGNYGenocea BiosciencesNASDAQ:GNCAQGenocea BiosciencesNASDAQ:GNCAAlvotechNASDAQ:ALVOView All Competitors CDAK Stock Analysis - Frequently Asked Questions How were Codiak BioSciences' earnings last quarter? Codiak BioSciences, Inc. (NASDAQ:CDAK) announced its earnings results on Thursday, November, 4th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.85) by $0.12. The firm earned $1.16 million during the quarter, compared to analyst estimates of $2.87 million. Codiak BioSciences had a negative net margin of 51.13% and a negative trailing twelve-month return on equity of 109.51%. When did Codiak BioSciences IPO? Codiak BioSciences (CDAK) raised $82 million in an initial public offering (IPO) on Wednesday, October 14th 2020. The company issued 5,500,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Evercore ISI, William Blair and Wedbush PacGrow served as the underwriters for the IPO. This page (NASDAQ:CDAK) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Codiak BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Codiak BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.